High-Tech Manufacturing Innovation Hub at RiverBend

Riverbend, a 1.2 million sq. ft. clean energy product manufacturing facility, operated by Tesla, an affiliate of Silevo LLC, is the largest NY CREATES project in Buffalo. Also known as Tesla Gigafactory New York (GFNY), the facility employs around 2,000 Western New York residents in clean energy, advanced manufacturing, and tech-related careers. GFNY is home to Tesla’s key energy and electric vehicle products, including Tesla’s electric vehicle DC fast charging equipment, which is deployed across the globe, and the power electronics that are deployed in the company’s utility-scale battery grid storage products.

Conventus Building on the Buffalo Niagara Medical Campus

This research site, located in the Conventus building on the Buffalo Niagara Medical Campus (BNMC), is Curia’s integrated small molecule drug discovery center. The site provides 43,000 sq. ft. of laboratories, writing areas, state-of-the-art equipment and informatics for drug discovery, and a team of approximately 100 scientists for project design and execution. A large percentage of the workforce has advanced degrees (Masters or Doctorate) from a New York university.

Curia Buffalo provides comprehensive drug discovery services to the National Institutes of Health, as well as to various biotech, not-for-profit and for-profit organizations working toward development of next-generation, life-changing therapies. Services provided include complex molecular and cellular analysis, assay development and screening, medicinal and computational chemistry, structural biology, and drug metabolism and pharmacokinetics (DMPK), among others.

ImmunityBio, Inc. (Dunkirk)

ImmunityBio acquired the lease-hold interest of the 409,000 square foot Dunkirk facility in February 2022 and continues to work through the construction processes necessary to bring the facility online. The company has received and is qualifying liquid and lyophilization high-speed lines and sterilizers. When complete, ImmunityBio believes this facility will be a state-of-the-art biotech production center that will provide the company with the ability to substantially expand and diversify its existing manufacturing capacity in the U.S., as well as provide the ability to scale production across the company’s key platforms.